FindTrial
Sign In

anti-PD-L1 antibody

DRUG3 trials

Sponsors

Lee's Pharmaceutical Limited, Roche Nederland B.V.

Conditions

Advanced Urothelial CarcinomaEsophageal Cancerlokaal gevorderd of gemetastaseerde urotheliale blaaskanker bladder cancer locally advanced or metastatic urothelial bladder cancer

Phase 1

A Study of Anti-PD-L1 Antibody in Neoadjuvant Chemotherapy of Esophageal Squamous Cell Carcinoma.
NCT04460066
Lee's Pharmaceutical LimitedEsophageal Cancer
Start: 2020-11-18End: 2023-07-15Target: 70Updated: 2022-05-04
A Study of Anti-PD-L1 Antibody ZKAB001 Combined With Albumin-bound Paclitaxel in Advanced Urothelial Carcinoma
NCT04603846
Lee's Pharmaceutical LimitedAdvanced Urothelial Carcinoma
Start: 2020-09-10End: 2023-08-25Target: 20Updated: 2022-01-24

Phase 3

A PHASE III, OPEN-LABEL, MULTICENTER, RANDOMIZED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF ATEZOLIZUMAB (ANTI*PD-L1 ANTIBODY) COMPARED WITH CHEMOTHERAPY IN PATIENTS WITH LOCALLY ADVANCED OR METASTATIC UROTHELIAL BLADDER CANCER AFTER FAILURE WITH PLATINUM-CONTAINING CHEMOTHERAPY
Active, not recruitingNL-OMON45200
Roche Nederland B.V.lokaal gevorderd of gemetastaseerde urotheliale blaaskanker bladder cancer locally advanced or metastatic urothelial bladder cancer
Start: 2015-06-08Target: 52Updated: 2024-02-28

Related Papers

Phase Ib study of anti-PD-L1 monoclonal antibody socazolimab in combination with nab-paclitaxel as first-line therapy for advanced urothelial carcinoma
The Oncologist2024-10-173 citations
Comparing a PD-L1 inhibitor plus chemotherapy to chemotherapy alone in neoadjuvant therapy for locally advanced ESCC: a randomized Phase II clinical trial : A randomized clinical trial of neoadjuvant therapy for ESCC.
2023-03-0832 citations
Phase Ib study of anti-PD-L1 monoclonal antibody socazolimab in combination with nab-paclitaxel as first-line therapy for advanced urothelial carcinoma.
Journal of Clinical Oncology2022-06-011 citations
Preoperative pembrolizumab combined with chemoradiotherapy for esophageal squamous cell carcinoma: Trial design.
2021-11-1023 citations